NSCLC patients from China with MET amplification (n = 30) and METex14 mutation (n = 30) will be treated with 1500 mg durvalumab and 300 to 600 mg savolitinib (OD) for 28-day/cycle till disease progression, death or toxicity. The gene discussed is MET; the disease is non-small cell lung carcinoma.